A protocol for high-throughput screening of histone lysine demethylase 4 inhibitors using TR-FRET assay

Identification of diverse chemotypes of selective KDM4 inhibitors is important for exploring and validating the roles of KDM4s in the pathogenesis of human disease and for developing therapies. Here, we report a protocol for high -throughput screening of KDM4 inhibitors using TR-FRET demethylation func-tional assay. We describe this protocol for screen of KDM4B inhibitors, which can be modified to screen inhibitors of other JmjC-domain-containing KDMs. For complete details on the use and execution of this protocol, please refer to Singh et al. (2021).